Feb 16, 2023 / 09:00AM GMT
Martin Olin - BerGenBio ASA - CEO
Good morning and welcome to BerGenBio's fourth-quarter financial report and business update. I'm Martin Olin, the CEO of BerGenBio. Today, I will, together with Cristina Oliva, our Chief Medical Officer, take you through a business update centered around our strategic focus in lung cancer and severe respiratory infections.
Just remind everyone about the formalities. So yesterday, BerGenBio announced the topline data from our second line non-small cell lung cancer study in which we have enrolled patients who have received at least one prior line of therapy, and the patients were treated in a combination of bemcentinib, our selective AXL inhibitor, in combination with pembrolizumab. And it's with great confidence that I can say that it actually does matter to inhibit AXL, specifically in non-small cell lung cancer.
The topline data we announced yesterday, very clearly show that AXL inhibition makes a difference. And we saw that in terms of very significant clinical benefit for the patients who received the combination of bemcentinib in combination with
Q4 2022 Bergenbio ASA Earnings Call Transcript
Feb 16, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers